NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Anixa Biosciences, Inc. (ANIX) Stock Analysis

Anixa Biosciences, Inc. (ANIX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ANIX

$3.07

+$0.02 (+0.66%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANIX with… →

ANIX Key Statistics

As of Sep 4, 2026
Trading
Open
$3.03
Previous Close
$3.05
Day's Range
3.00–3.11
52-Week Range
2.32–5.46
Volume
367.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.52
Valuation
Market Cap
$104.45M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
−0.11
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.30
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$10.93M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
34.02M
1-Year Return
+3.37%
Dividend and dates
Earnings Date
September 9, 2026
Avg Volume
271.44K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ANIX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−1.60%
2025+34.48%
2024−40.21%
2023−8.71%
2022+43.10%
2021−3.26%
2020−6.40%
2019−16.75%
2018+66.95%
2017−56.30%
2016 (partial year)+74.19%

As of September 4, 2026.

ANIX Revenue and Earnings by Fiscal Year

FY ends October
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$10.93M—
2024$0.00−$12.55M—
2023$210.00K−$9.81M−4671.9%
2022$0.00−$13.60M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$11.70M−$10.93M—
2024$0.00$0.00−$13.83M−$12.55M—
2023$210.00K$49.00K−$11.01M−$9.81M−4671.9%
2022$0.00$0.00−$13.88M−$13.60M—

Annual figures as reported, in the company's reporting currency. As of October 31, 2025.

ANIX Valuation vs Biotechnology Median

Median of 656 stocks
MetricANIXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Anixa Biosciences, Inc. (ANIX) at $104.45M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 4.

The 52-week range on file runs from $2.32 to $5.46. The most recent close on file for ANIX is $3.07, dated September 4, 2026. That is +$0.02 (+0.66%) against the previous close. The latest close sits 32.33% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $10.93M. Profit margin runs at 0%. Trailing earnings per share are −0.3.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads −0.11.

Over the trailing twelve months the price has returned +3.37%. Measured over 10 years, that is −3.06% a year compounded. Beta against the wider market is reported at 0.52. Annualized volatility over the trailing 10 years is 93.54%.

Growth & Income

The record shows no dividend for ANIX.

So far in 2026 the price is −1.60%. Across the complete calendar years on file, 2018 returned +66.95% and 2017 returned −56.30%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Anixa Biosciences, Inc. (ANIX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Anixa Biosciences, Inc. ANIX $104.45M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Anixa Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Visit website →